Prognostic role of EphA2 in various human carcinomas: a meta-analysis of 23 related studies

References

• Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, et al. 2005. EphB receptor activity suppresses colorectal cancer progression. Nature 435:1126–1130
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
   PubMed Web of Science ®Google Scholar
• Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. 2009. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15:4423–4430
   PubMed Web of Science ®Google Scholar
• Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, Chen X. 2007. Quantitative radioimmuno PET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 34:2024–2036
   PubMedGoogle Scholar
• Clifford N, Smith LM, Powell J, Gattenlohner S, Marx A, O'Connor R. 2008. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem 105:1250–1259
   Google Scholar
• Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, et al. 2003. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 63:7907–7912
   PubMed Web of Science ®Google Scholar
• Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG. 2010. EFNA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma. Int J Cancer 126:940–949
   PubMed Web of Science ®Google Scholar
• Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. 1999. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84:494–501
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
   PubMed Web of Science ®Google Scholar
• Fan M, Liu Y, Xia F, Wang Z, Huang Y, Li J, Wang Z, Li X. 2013. Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma. Tumori 99:689–696
   Google Scholar
• Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, et al. 2010. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 285:18575–18585
   PubMed Web of Science ®Google Scholar
• Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, et al. 2013. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol 8:301–308
   Google Scholar
• Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, et al. 2004. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490–499
   PubMed Web of Science ®Google Scholar
• Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z. 2005. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99:278–286
   PubMed Web of Science ®Google Scholar
• Himanen JP, Nikolov DB. 2003. Eph receptors and ephrins. Int J Biochem Cell Biol 35:130–134
   PubMedGoogle Scholar
• Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F. 1987. A novel putative tyrosine kinase receptor encoded by the eph gene. Science (New York, NY) 238:1717–1720
   Google Scholar
• Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB. 2008. Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci 5:121–126
   PubMedGoogle Scholar
• Holm R, Knopp S, Suo Z, Trope C, Nesland JM. 2007. Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis. J Clin Pathol 60:1086–1091
   PubMedGoogle Scholar
• Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, et al. 2012. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol (Northwood, London, England) 29:2691–2700
   Google Scholar
• Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, et al. 2012. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 76:431–438
   Google Scholar
• Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, et al. 2009. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115:2684–2692
   Google Scholar
• Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, et al. 2002. Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 128:343–348
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Kaibe N, Morimoto K, Fukui H, Niwa H, Maeyama Y, Takemura M, et al. 2014. Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer. Gastric Cancer. [Epub ahead of print]
   Google Scholar
• Kinch MS, Moore MB, Harpole DH. 2003. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613–618
   PubMed Web of Science ®Google Scholar
• Landen CN Jr., Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, et al. 2006. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98:1558–1570
   PubMed Web of Science ®Google Scholar
• Li X, Wang L, Gu JW, Li B, Liu WP, Wang YG, Zhang X, et al. 2010. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumour Biol 31:477–488
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Qiu Y, Huang D, Zhang S, Xie L, Qi L, et al. 2011. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol 137:761–769
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. 2005. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387–391
   PubMed Web of Science ®Google Scholar
• Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, et al. 2010. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Therapy 10:1306–1314
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. 2013. EphA4 is a prognostic factor in gastric cancer. BMC Clinical Pathology 13:19
   PubMedGoogle Scholar
• Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. 2003. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103:657–663
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6:e1000097
   PubMed Web of Science ®Google Scholar
• Nakamoto M, Bergemann AD. 2002. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59:58–67
   PubMed Web of Science ®Google Scholar
• Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, Ravshanov S, et al. 2005. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96:42–47
   PubMed Web of Science ®Google Scholar
• Palmer A, Klein R. 2003. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev 17:1429–1450
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. 1998. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
   PubMed Web of Science ®Google Scholar
• Shao Z, Zhang WF, Chen XM, Shang ZJ. 2008. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: Correlation with the angiogenesis and clinical outcome. Oral Oncol 44:1110–1117
   Google Scholar
• Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, et al. 2001. Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis. Eur Resp J 18:705–719
   PubMed Web of Science ®Google Scholar
• Surawska H, Ma PC, Salgia R. 2004. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15:419–433
   PubMed Web of Science ®Google Scholar
• Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, et al. 2004. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145–5150
   PubMed Web of Science ®Google Scholar
• Toma MI, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S, Wirth MP, Baretton GB. 2014. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PloS One 9:e102262
   Google Scholar
• Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, et al. 2008. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19:151–156
   PubMed Web of Science ®Google Scholar
• Wilkinson DG. 2001. Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2:155–164
   PubMed Web of Science ®Google Scholar
• Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z. 2005. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res 25:2943–2950
   PubMed Web of Science ®Google Scholar
• Yang P, Yuan W, He J, Wang J, Yu L, Jin X, Hu Y, et al. 2009. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 39:1169–1177
   PubMed Web of Science ®Google Scholar
• Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H, Yang P, Hu B, et al. 2009. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 54:2410–2417
   PubMedGoogle Scholar
• Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306
   PubMed Web of Science ®Google Scholar